Clinical Trial Update: PTK787 in Patients With Advanced Metastatic Pancreatic Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for PTK787 (Vatalanib) in advanced metastatic pancreatic adenocarcinoma; the study status is listed as completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma

Drugs mentioned

• PTK787 (Vatalanib)

Snippet

Sponsor: Pancreatic Cancer Research Team | Conditions: Neoplasm | Phase 2 | Status: COMPLETED